BINEX Co., Ltd.
Financials
Valuation Metrics
BINEX Co., Ltd.'s Market Cap is ₩2239B. At end of 2025 it was ₩4896B. Ranked #761 of 2,436 in KR market (top 31%), #334 of 1,649 on KOSDAQ (top 20%), #85 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 223.89B KRW | KR#761/2,436 Sec#85/234 |
| Revenue | 164.00B KRW | KR#1,116/2,436 Sec#67/234 |
| Net Income | -12.92B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 316.45B KRW | KR#992/2,436 Sec#66/234 |
| Net Assets | 180.02B KRW | KR#987/2,436 Sec#70/234 |
| Employees | 671 | KR#372/2,436 Sec#31/234 |
| Value | ||
| P/B | 1.24x | KR#1,672/2,436 Sec#116/234 |
| P/S | 1.37x | KR#1,602/2,436 Sec#93/234 |
| Profitability | ||
| ROE | -7.18% | KR#1,817/2,436 Sec#137/234 |
| ROA | -4.08% | KR#1,843/2,436 Sec#135/234 |
| Op. Margin | -8.57% | KR#1,948/2,436 Sec#131/234 |
| Revenue Growth | -11.24% | KR#1,910/2,436 Sec#175/234 |
| Financial Health | ||
| Debt Ratio | 75.79% | KR#258/2,436 Sec#34/234 |
| Total Debt | 91.87B KRW | KR#745/2,436 Sec#47/234 |
| Cash | 22.36B KRW | KR#1,176/2,436 Sec#85/234 |
| Current Ratio | 1.50x | KR#1,301/2,436 Sec#141/234 |
| Performance | ||
| 1Y Return | -57.85% | KR#2,210/2,436 Sec#208/234 |
| 1M Return | -7.81% | KR#1,616/2,436 Sec#164/234 |
| From 52W High | -64.32% | KR#1,923/2,436 Sec#163/234 |
| 1Y MDD | -67.87% | KR#1,844/2,436 Sec#155/234 |
| Trading | ||
| Volume | 79,530 shares | KR#1,070/2,436 Sec#103/234 |
| Foreign Own. | 8.06% | KR#560/2,436 Sec#51/234 |
| Per Share | ||
| EPS | -393 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,648 KRW | KR#1,353/2,436 Sec#98/234 |
Company Info
Established in 1957, the company changed its name to Binex in 2000, listed on KOSDAQ in 2001, and expanded its business in 2015. It operates chemical pharmaceutical manufacturing and biopharmaceutical CDMO businesses, producing over 120 products in Busan and providing CDMO services in Songdo and Osong. To advance as a global CDMO, the company has passed GMP audits and plans to obtain cGMP certification and expand production capacity through an FDA audit in 2025, solidifying its standing as a global bio hub. Binex is headquartered in Saha-gu, Busan.